Florida Cancer Specialists - South

Summary

Florida Cancer Specialists - South is a medical facility located in Fort Myers, Florida. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer and other specialties. Florida Cancer Specialists - South is involved with conducting 79 clinical trials across 112 conditions. There are 9 research doctors associated with this hospital, such as Fadi Kayali, MD, Ivor J Percent, Vance M. Wright-Browne, and Lowell L Hart.

Top PIs

Clinical Trials running at Florida Cancer Specialists - South

Colorectal Cancer

Small Cell Lung Cancer

Lung Cancer

Multiple Myeloma

Prostate Cancer

Endometrial Cancer

Pancreatic Cancer

Ovarian Cancer

Breast Cancer

Chronic Lymphocytic Leukemia

Amivantamab + Chemotherapy vs Cetuximab + Chemotherapy

for Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type (WT) unresectable or metastatic left-sided colorectal cancer.

Recruiting

2 awards

Phase 3

4 criteria

Amivantamab + FOLFIRI

for Colorectal Cancer

The purpose of this study is to compare how long the participants are disease-free (progression-free survival) and and the length of time until a participant dies (overall survival), when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus either cetuximab or bevacizumab and FOLFIRI given to participants with Kirsten rat sarcoma viral oncogene/ neuroblastoma RAS viral oncogene homolog (KRAS/ NRAS) and v-raf murine sarcoma viral oncogene homolog B (BRAF) wild-type recurrent, unresectable or metastatic colorectal cancer who have previously received chemotherapy.

Recruiting

2 awards

Phase 3

4 criteria

Zanidatamab

for Breast Cancer

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Recruiting

1 award

Phase 2

5 criteria